Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10714746 | 0.87 | MEN1 (0.54) | VCAM1MEN1KMT2ATTRALB | |
| SCHEMBL10717379 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2ATTRALBTHRB | |
| SCHEMBL31009400 | 0.81 | APLNR (0.45) | VCAM1MEN1KMT2ATTRTDP1 | |
| SCHEMBL31009481 | 0.81 | MEN1 (0.53) | VCAM1MEN1KMT2ATTRTDP1 | |
| SCHEMBL27781910 | 0.80 | KDM4E (0.50) | MEN1KMT2ATTRALBTHRB | |
| SCHEMBL476349 | 0.80 | ALDH1A1 (0.58) | MEN1KMT2ATTRALBTHRB | |
| SCHEMBL2271210 | 0.80 | SMN1; SMN2 (0.54) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL1602832 | 0.80 | MAPK1 (0.51) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL6158782 | 0.80 | ALDH1A1 (0.56) | MEN1KMT2ATTRALBTHRB | |
| SCHEMBL28972085 | 0.79 | PIN1 (0.55) | VCAM1MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1539708-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192748-A1 | Heterocyclic compounds | BOEHRINGER INGELHEIM PARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004024699-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-4438126-A | Lower alkanoic acid derivatives of 2-oxo-benzoxazolines and aldose reductase inhibiting compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-20 | — | — | US | disclosed |
| EP-0022317-B1 | 2-OXO-BENZOTHIAZOLINE, BENZOXAZOLINE OR INDOLINE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-21 | — | — | EP | disclosed |
| US-4370340-A | ANTIDIABETIC AGENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-25 | — | — | US | disclosed |
| EP-0022317-A1 | 2-Oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | VCAM1 4819/4885MEN1 374/4885KMT2A 1103/4885 |
| US-20040192748-A1 | Heterocyclic compounds | IL1B, CCL5, IL4 | VCAM1 159/4885MEN1 3627/4885KMT2A 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.